ReviewFrontiers in cardiovascular medicine2021
Rationale for the Use of Pirfenidone in Heart Failure With Preserved Ejection Fraction.
Review in Frontiers in cardiovascular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05531955 (A Study of Pirfenidone in the Treatment of Myocardial Fibrosis After Acute Myocardial Infarction), which is not on this map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Study of Pirfenidone in the Treatment of Myocardial Fibrosis After Acute Myocardial Infarction: a Phase II Prospective, Randomized, Double-blind，Placebo Controlled Clinical Trial
Who cites it
9 citing papers in PubMed, 9 citations in OpenAlex.
- Serum metabolomic signatures integrating sphingosine-1-phosphate and tetrahydrocortisone improve prognostic assessment in non-ischemic cardiomyopathy.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Integrative Perspectives on Pirfenidone: Mechanistic Insights, Pharmacodynamics, and Emerging Therapeutic Strategies for Fibrotic Disorders.AAPS PharmSciTech · 2026Review
- The unexplored mechanism of antitumoral effect of pirfenidone in melanoma cells.Scientific reports · 2025Article
- Pirfenidone reduces ovarian fibrosis and improves PCOS in letrozole-induced rat model.Biomolecules & biomedicine · 2025Article
- Pirfenidone mitigates demyelination and electrophysiological alterations in multiple sclerosis: Targeting NF-κB, sirt1, and neurotrophic genes.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Therapeutic Approaches in Heart Failure with Preserved Ejection Fraction (HFpEF) in Children: Present and Future.Paediatric drugs · 2022Review
- Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond.Cardiac failure review · 2022Review
- Pharmacological basis of the antifibrotic effects of pirfenidone: Mechanistic insights from cardiacFrontiers in cardiovascular medicine · 2022Review
- Modulation of Cardiac Fibrosis in and Beyond Cells.Frontiers in molecular biosciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure with preserved ejection fraction (HFpEF) is a major public health problem with growing prevalence and poor outcomes, mainly due to the lack of an effective treatment. HFpEF pathophysiology is heterogeneous and complex. Recently a "new paradigm" has been proposed, suggesting that cardiovascular and non-cardiovascular coexisting comorbidities lead to a systemic inflammatory state, perturbing the physiology of the endothelium and the perivascular environment and engaging molecular pathways that ultimately converge to myocardial fibrosis. If inflammation and fibrosis are the "
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.